Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;8(2):161-169.
doi: 10.1016/j.ajur.2021.03.001. Epub 2021 Mar 6.

Treatment of clinical stage I non-seminoma

Christian Winter  1 , Andreas Hiester  1
Affiliations
Review

Treatment of clinical stage I non-seminoma

Christian Winter et al. Asian J Urol. 2021 Apr.

Abstract

Germ cell cancers are the most common solid tumors among men between 15 and 40 years. Non-seminomatous germ cell tumors (NSGCTs) represent a unique and exclusive cohort of germ cell tumor patients. Non-seminoma can harbor different histologic components. The most commonly found histologies are embryonal cell cancer, teratoma, yolk sack tumor and choriocarcinoma, as well as teratocarcinoma and seminoma, in combination with non-seminomatous germ cell tumors histologic types. The clinical definition of stage I non-seminoma is the absence of metastatic lesions on imaging and normal tumor markers. The cure rate for clinical stage I NSGCT is 99% and this can be achieved by three therapeutic strategies: Active surveillance with treatment at the time of relapse, retroperitoneal lymph node dissection or adjuvant chemotherapy. The balancing of these various strategies should always be based on an individual risk profile of NGSCG patient depending on the lymphovascular invasion of the tumor.

Keywords: Active surveillance; Germ cell tumors; Non-seminomatous germ cell tumors; Retroperitoneal lymph node dissection.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The worldwide incidence for testis cancer Incidence. (A) 1-year and 5-year prevalence and number of deaths in 2018 for testicular cancer; (B) Expected number of incident cases and deaths from 2018 to 2040 for testicular cancer. (GLOBOCAN 2018, https://gco.iarc.fr/).
Figure 2
Figure 2
The results of histochemical staining. (A) Microscope slides of yolk sac (10×); (B) embryonal cell carcinoma (5×); (C) choriocarcinoma (10×); (D) teratoma (5×).
Figure 3
Figure 3
Relapse rates according to different treatment strategies for NSGCT stage I [39,40]. RPLND, retroperitoneal lymph node dissection; NSGCT, non-seminomatous germ cell tumors; BEP, bleomycin, etoposide, and cisplatin.
Figure 4
Figure 4
Flowsheet of treatment of NSGCT stage I (modified after [4]). NSGCT, non-seminomatous germ cell tumors; LVI+, lymphovascular invasion; LVI−, no lymphovascular invasion; IGCCCG, International Germ Cell Cancer Collaborative Group; BEP, bleomycin, etoposide, and cisplatin; NS-RPLND, nerve-sparing retroperitoneal lymph node dissection; NSGCT, non-seminomatous germ cell tumor; CSI, clinical stage I.
See this image and copyright information in PMC

References

    1. Shanmugalingam T., Soultati A., Chowdhury S., Rudman S., Van Hemelrijck M. Global incidence and outcome of testicular cancer. Clin Epidemiol. 2013;5:417–427. - PMC - PubMed
    1. Le Cornet C., Lortet-Tieulent J., Forman D., Béranger R., Flechon A., Fervers B. Testicular cancer incidence to rise by 25% by 2025 in Europe? Model-based predictions in 40 countries using population-based registry data. Eur J Canc. 2014;50:831–839. - PubMed
    1. Ghazarian A.A., Trabert B., Devesa S.S., McGlynn K.A. Recent trends in the incidence of testicular germ cell tumors in the United States. Andrology. 2015;3:13–18. - PMC - PubMed
    1. Albers P., Albrecht W., Algaba F., Bokemeyer C., Cohn-Cedermark G., Fizazi K. Guidelines on testicular cancer: 2015 update. Eur Urol. 2015;68:1054–1068. - PubMed
    1. Wittekind C. [TNM classification of testicular tumors. Definitions and prerequisites for correct application] Pathologe. 2014;35:252–255. [Article in German] - PubMed

LinkOut - more resources